MicroPort Orthopedic Products Received First International Order

On July, 2011, MicroPort Orthopedics Co., Ltd., a wholly owned subsidiary of MicroPort Medical (Shanghai) Co., Ltd., received a blanket purchase order from a key international distributor, for spine implants and other related products of certain amount. This is the first international order, and also represents the very first sale of the company since its establishment in 2009.

MicroPort Register’s Hercules Success in Thailand

Registration for Hercules Thoracic Stent-Graft System in Thailand has been approved by the Thai FDA (Thai Food and Drug Administration) on July, 2011. The medical application of this product is intended for the treatment of aortic aneurysm repair.

Columbus™ and Voyager™ Unveiled in the 9th China Atrial Fibrillation Symposium (CAFS)

On August 5, 2011, MicroPort EP products, Columbus™ 3D electrophysiological mapping system and Voyager™ irrigated RF ablation catheter, recently completed the first-in-man clinical studies, have been unveiled in the 9th China Atrial Fibrillation Symposium (CAFS) through the case broadcast session. The experts gave their comments on the on-site procedure performed by Dr. Ronghui Yu of Beijing An Zhen Hospital. This is the first time MicroPort EP products have participated in the case broadcast at the national academic symposium. The results of which provide an excellent foundation for further large-scale clinical studies. MicroPort also organized a satellite session during the symposium which attracted attention from across the industry.

The Clinical Trial TARGET II Launched

MicroPort Medical Corporation announced the launch of TARGET II Firehawk, in Beijing on August 12, 2011. Target II Firehawk, is the single-arm multicenter clinical study for MicroPort’s Firehawk; the new generation of drug-eluting stent systems. The pre-market clinical trials of Firehawk can be classified into 3 stages including FIM, TARGET I, and TARGET II. It is planned to be conducted in more than 30 clinical centers around the country which would enroll 716 patients. Mr. Runlin Gao, an academic from Fuwai Hospital for Cardiovascular Disease and Mr. Bo Xu, Director of Fuwai Hospital for Cardiovascular, served as principal investigator and project secretary respectively. They gave a brief introduction on the three clinical stages and made a summary of TARGET I with Mr. Hualin Liu from China Cardiovascular Research Foundation. Currently, the 4-month OCT follow-up of FIM has been finished, according to which the success rate and endothelial cell coverage rate is 100% and 96.2% respectively, with a zero incidence of MACE. And the 13-month angiographic follow-up showed that the average in-stent late lumen loss was 0.16 mm. 510 implant cases of TARGET I have already been finished and the follow-up is on the way. We believe the clinical trial will play an important part in assessing the safety and effectiveness of the stents more precisely, and provide more valuable information and the scientific basis for long-term application.

The Clinical Trials of FutagoTM Thoracic & Lumbar Fusion Device Is on Schedule

The pre-approved multicenter randomized controlled clinical trial, concerning Efficacy and Safety of Futago™ Thoracic & Lumbar Fusion Device for the treatment of Degenerative Disc Disease and Spondylolisthesis, and currently being conducted under the supervision of SFDA, made significant progress this July. Implantation in the test group and control group at several clinical centers including, Beijing, Shanghai, Zhejiang, and Hebei, has been completed with 100% success rate. And further, the 3-month and 6-month clinical follow-up results for patients with early implants were excellent.